Product Description
Pfizer was developing an-2718, a topical LeuRS inhibitor, for the treatment of tinea pedis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00781664)
Mechanisms of Action: LeuRS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Tinea Pedis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AN2718-TP-101 | P1 |
Completed |
Tinea Pedis |
2008-11-01 |
22% |